Flemming Ørnskov led Shire's expansion into rare diseases before the drugmaker's USD 62bn (DKK 399.3bn) sale to Takeda Pharmaceutical Co. in 2019. Now he's plotting a new course for a skincare business that Nestle SA gave up on.
Ørnskov, who took the reins of Switzerland-based Galderma two years ago, said in an interview that he's "doubling down on science," accelerating research spending and adding dermatologists and medical specialists as the company prepares for a potential initial public offering.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.